Elise Heon, Deep Genomics (S), Janssen (C), Novartis (R), Novartis (C);
B. Melia, None;
Laura Bocchino, None;
Jacque Duncan, 4D Therapeutics (C), Acucela (F), AGTC (C), Allergan/Abbvie (F), Astellas (C), Biogen/Nightstarx Therapeutics (F), DTx Therapeutics (C), Editas (C), Eloxx (C), Eyevensys (C), Gyroscope (C), Horama (C), Neurotech USA (F), ProQR Therapeutics (C), Second Sight Medical Products (F), Sparing Vision (C), Spark Therapeutics (C), Spouse- RxSight (F), Vedere Bio (C);
Allison Ayala, None;
Chris Bradley, None;
Isabelle Audo, Agence Nationale de la Recherche within the Investissements d'Avenir program [ANR-11-IDEX-0004-0] (F), Biogen (C), Gamut Tx (C), IHU FOReSIGHT [ANR-18-IAHU-0001] (F), LABEX LIFESENSES [reference ANR-10-LABX-65] (F), MeiraGTX (C), Novartis (C), Retina France (F), Roche (C);
Janet Cheetham, Abbvie (I);
Gislin Dagnelie, None;
Todd Durham, None;
Carel Hoyng, None;
Nieraj Jain, None;
Thiran Jayasundera, None;
Mark Pennesi, Adverum (C), AGTC (C), Allergan/Editas (C), Astellas Pharmaceuticals (C), Astena (C), Biogen (C), Blue Rock (C), DTx (C), Endogena (C), Eyevensys (C), Gensight (C), Horama (C), Iveric (C), Nacuity Pharmaceuticals (C), Novartis (C), Nyan (C), Ocugen (C), Ora (C), ProQR Therapeutics (C), RegenexBio (C), Roche (C), Sanofi (C), Sparing Vision (C), Vedere (C), Viewpoint Therapeutics (C);
Christina Weng, Alcon (C), Alimera Sciences (C), Allergan/Abbvie (C), DORC (C), Genentech (C), Novartis (C), Regeneron (C), Regenxbio (C)